Novavax developing vaccine that targets new COVID-19 variant

By Manojna Maddipatla and Mrinalika Roy (Reuters) -Novavax Inc said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks. The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529. “The initial work will take a few weeks,” a…

Read More